Présentation de l'entreprise
DiaMedica Therapeutics Inc. operates as a clinical stage biopharmaceutical entity dedicated to enhancing the quality of life for individuals afflicted by severe ischemic diseases. The company functions within the healthcare sector, specifically the biotechnology industry, which implies a focus on early-stage research and development rather than mature commercial product sales. With a total market capitalization of $333.53M, the firm employs approximately 35 people and currently reports no annual revenue figures as indicated by the available data. The absence of reported revenue alongside a market cap of $333.53M signifies that the company's valuation is driven primarily by future potential and asset value rather than current cash generation, a common characteristic for firms in the clinical stage of development.
Santé financière
The company reports no revenue for the trailing twelve months, a net income of $-32,766,000, and an EBITDA of $-34,354,000. The structural gap between zero revenue and significant negative net income reveals a cost structure entirely dependent on research expenditures and operational overhead without offsetting commercial income. Free cash flow stands at $-18,192,124, which indicates that the company is burning through capital reserves to fund its clinical trials and operational activities. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, reflecting the typical financial profile of a pre-revenue biotechnology firm where costs exceed any direct product sales. The balance sheet holds $59.89M in cash against $240,000 in debt, resulting in a debt-to-equity ratio of 0.43. This disparity between substantial cash holdings and minimal debt suggests a conservative balance sheet approach despite the negative earnings. Furthermore, a current ratio of 11.81 demonstrates an exceptionally strong short-term liquidity position, providing ample resources to cover current liabilities. Return on Equity is -67.7% and Return on Assets is -39.9%, metrics that indicate management is utilizing the company's capital base to generate negative returns in the short term, consistent with the heavy investment phase of clinical development.
Évaluation de la valorisation
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed at -7.40. The distinction between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in future earnings expectations that have not yet been realized or are anticipated to remain negative in the near term. The price-to-book ratio is 5.93, indicating that the market values the company at nearly six times its net asset book value, a premium often attributed to the intangible value of its pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -7.97, further highlight that traditional multiple-based valuation models are not applicable until the company generates positive cash flows and sales. The stock has traded between a 52-week low of $3.26 and a 52-week high of $10.42. Without a specific current price provided in the facts, the valuation context is defined by this volatility range, where the negative forward P/E suggests the market is discounting current cash flows heavily. The beta of 1.15 indicates that the stock price is expected to be 15% more volatile than the broader market, reflecting the high-risk nature of clinical stage biotechnology investments.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, precluding a direct comparison of growth rates between top-line and bottom-line performance. Since the company has not yet generated revenue, earnings cannot grow faster than revenue in the traditional sense, as both metrics are currently absent from the historical data. DiaMedica Therapeutics Inc. does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available earnings and cash flow into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete lack of current financial returns, with the entire corporate strategy focused on advancing the lead candidate DM199 through Phase 2/3 trials to eventually achieve commercial viability.